Quent Capital’s Biofrontera BFRI Stock Holding History

Quent Capital’s Portfolio BFRI Stock Details BFRI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-89	Closed	-$1.09K	–	1327
2023 Q1	$1.09K	Hold	89	–	–	﹤0.01%	1237
2022 Q4	$1.64K	Buy	+89	New	+$1.82K	﹤0.01%	1173

Other funds holding BFRI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bard Associates Chicago, Illinois $398M AUM 54.32% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Quent Capital's BFRI Position: Q2 2023 in Review

Quent Capital sold out of Biofrontera (BFRI) in Q2 2023, closing a stake of 89 shares — an estimated $1.09K sold.

Quent Capital first reported a position in BFRI in Q4 2022 and held it in 2 quarters. The position peaked at $1.64K in Q4 2022. 13 funds tracked by Wall St. Rank hold BFRI as of Q2 2023.

Quent Capital reported no remaining Biofrontera position as of Q2 2023 after selling out during the quarter.
Quent Capital sold 89 Biofrontera shares in Q2 2023, an estimated $1.09K.
Quent Capital first reported a position in Biofrontera in Q4 2022 and held it in 2 quarters.
Quent Capital's Biofrontera position peaked at $1.64K in Q4 2022.
13 funds tracked by Wall St. Rank held Biofrontera as of Q2 2023.

Based on Quent Capital's 13F filing for Q2 2023, filed 10 Jul 2023.